The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abstract
PURPOSE: A phase I study was undertaken to determine the maximum-tolerated dose (MTD), principal toxicities, and pharmacokinetics of the novel topoisomerase I inhibitor irinotecan (CPT-11). PATIENTS AND METHODS: Sixty-four patients meeting standard phase I eligibility criteria were included (24 women, 40 men; median age, 51 years; primary sites: colon, head and neck, lung, pleura; 60 of 64 had been previously treated). Pharmacokinetics was determined by high-performance liquid chromatography (HPLC). RESULTS: One hundred ninety CPT-11 courses were administered as a 30-minute intravenous (IV) infusion every 3 weeks (100 to 750 mg/m2). Grade 3 to 4 nonhematologic toxicities included diarrhea (16%; three hospitalizations), nausea and vomiting (9%), asthenia (14%), alopecia (53%), elevation of hepatic transaminases (8%), and one case of skin toxicity. An acute cholinergic syndrome was observed during CPT-11 administration. Diarrhea appeared dose-limiting at 350 mg/m2, but this was circumvented by using a high-dose loperamide protocol that allowed dose escalation. Dose-dependent, reversible, noncumulative granulocytopenia was the dose-limiting toxicity (nadir, days 6 to 9; median recovery time, 5 days). Grade 3 to 4 anemia was observed in 9% of patients. One patient died during the study, 8 days after CPT-11 treatment. Two complete responses (cervix, 450 mg/m2; head and neck, 750 mg/m2) and six partial responses in fluorouracil (5-FU)-refractory colon cancer were observed (260 to 600 mg/m2). Pharmacokinetics of CPT-11 and active metabolite SN-38 were performed in 60 patients (94 courses). CPT-11 plasma disposition was bi- or triphasic, with a mean terminal half-life of 14.2 +/- 0.9 hours (mean +/- SEM). The mean volume of distribution (Vdss) was 157 +/- 8 L/m2, and total-body clearance was 15 +/- 1 L/m2/h. The CPT-11 area under the plasma concentration versus time curves (AUC) and SN-38 AUC increased linearly with dose. SN-38 plasma decay had an apparent half-life of 13.8 +/- 1.4 hours. Both CPT-11 and SN-38 AUCs correlated with nadir leukopenia and granulocytopenia, with grade 2 diarrhea, and with nausea and vomiting. CONCLUSION: The MTD of CPT-11 administered as a 30-minute IV infusion every 3 weeks is 600 mg/m2, with granulocytopenia being dose-limiting. At 350 mg/m2, diarrhea appeared dose-limiting, but high-dose loperamide reduced this toxicity and allowed dose escalation. For safety reasons, the recommended dose is presently 350 mg/m2 every 3 weeks; more experience must be gained to establish the feasibility of a higher dose in large multicentric phase II studies. However, when careful monitoring of gastrointestinal toxicities is possible, a higher dose of 500 mg/m2 could be recommended in good-risk patients. The activity of this agent in 5-FU-refractory colorectal carcinoma makes it unique and mandates expedited phase II testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS
Liu, L. F. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.002031 · Cited by 1,811
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
The Current Status of Camptothecin Analogues as Antitumor Agents
Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., & Kaufmann, S. H. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.271 · Cited by 618
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., & Kaufmann, S. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.647 · Cited by 353
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
Hsiang, Y. H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., & Potmĕsil, M. (1989) · PubMed · Cited by 339
Cited by
Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs
Lu, J., Liong, M., Zink, J. I., & Tamanoi, F. (2007) · Small · doi:10.1002/smll.200700005 · Cited by 1,012
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“…5–40 mg/m2 5D, continuously No Yesd ND ND de Forni et al., 1994 [186] 59 50–145 mg/m2 Q1W Yese Yese ND ND Rowinsky et al., 1994 [65] 32 100–345 mg/m2 Q3W No Yese ND ND Abigerges et al., 1995 [187] 64 100–750 mg/m2 Q3W Yesd Yesd ND ND Catimel et al., 1995 [67] 46 33–115 mg/m2 D1–D3, Q3W No No ND…”
InfluentialIrinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344
Metadata
- Authors
- Abigerges, D., Chabot, G. G., Armand, J. P., Hérait, P., Gouyette, A., & Gandia, D.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-01
- Volume
- 13
- Issue
- 1
- Pages
- 210-221
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1774923611
- Cited by
- 299
- References
- 28
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. https://app.cochat.ai/papers/10.1200/jco.1995.13.1.210
- The paper
- Abigerges, D., Chabot, G. G., Armand, J. P., Hérait, P., Gouyette, A., & Gandia, D. (1995). Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.1.210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.